NCT03654105 2026-03-27
SMILE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT04184921 2026-02-03
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT03543683 2025-02-27
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT06018688 2023-09-21
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT01707823 2020-01-14
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Terminated
NCT02123849 2018-08-29
Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
National Cancer Institute (NCI)
Phase 2 Completed
NCT01058902 2016-03-07
The Effect Of Aspirin On Survival in Lung Cancer
Liverpool Heart and Chest Hospital NHS Foundation Trust
Phase 3 Withdrawn
NCT02387086 2015-03-12
Gefitinib Combined With Thalidomide to Treat NSCLC
Shaanxi Provincial People's Hospital
Phase 2/3 Unknown